Articles from ConcertAI

ConcertAI's TeraRecon, a leader in integrating advanced imaging workflows with clinical AI, has announced an expanded partnership with 3DR® Labs, a leading provider of 3D medical image post-processing and clinically integrated AI services in the United States. This collaboration aims to enhance clinical service delivery for advanced imaging by expanding the range of domain-specific workflows and clinical AI technologies. As a result, it will benefit numerous hospitals across the country.

ConcertAI, a leader in oncology predictive and generative AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences is presenting and exhibiting at NVIDIA GTC25 in San Jose, CA. ConcertAI will showcase the latest advances in the CARAai™ platform with a multi-agentic AI development and deployment framework, proprietary multi-small language model (SLM), and multi-large language models (LLMs) tuned for different aspects of oncology insights and clinical development. Many of the AI SaaS solutions being presented and demonstrated at GTC25 are part of the ConcertAI collaboration with NVIDIA announced in June 2024.

At the opening of SCOPE 2025, ConcertAI and Exigent Research announced the availability of ConcertAI technologies for study feasibility, patient-to-trial matching, and AI-powered study automations across all Exigent research sites and as an integral part of all sponsored studies. The partnership ensures that advanced CARAai™ Generative and Agentic AI solutions are available to provide the highest possible performance and lowest burden for the network’s leading community research sites. A few weeks earlier, NeoGenomics and ConcertAI announced the collaborative launch of an AI Software-as-a-Service solution for hematological malignancies, guiding protocol optimization and study design for all major hematological diseases with exceptional biomarker depth and data longitudinality.

Exigent Research and ConcertAI announced a major multi-year partnership to assure potentially lifesaving clinical trials are available to the broadest population of patients possible, combining the growing Exigent community oncology research network with a full suite of ConcertAI technologies providing study feasibility, patient-to-trial matching, and AI-powered study automations.

ConcertAI, a leader in oncology predictive, generative, and agentic AI SaaS and Real-World Data (RWD) solutions for healthcare and life sciences, today outlined its FY2024 business results, key partnerships, and future roadmap at the 43rd annual J.P. Morgan Healthcare Conference.

ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collaboration jointly announced on Jan. 8, 2024, and the more recent joint research completed and scheduled for presentation at the 2024 American Society of Hematology Meeting on Monday, Dec. 9, in San Diego.

ConcertAI, the leader in predictive and generative AI SaaS and DaaS solutions for healthcare and life sciences, today announced a Software-as-a-Service (SaaS) cloud version of TeraRecon’s AI-enabled portfolio of advanced visualization (AV) and generative AI modules for clinical workflows. This is a milestone in making the best-in-class solution more accessible to healthcare providers, and brings together Intuition Advanced Visualization, Eureka Clinical AI, and CARAai™ in one cloud platform. This addition of the SaaS platform allows healthcare organizations to utilize the latest TeraRecon solutions in different configurations at the enterprise and network levels and assures consistency in AI enabled-workflows everywhere.

TeraRecon, the leader in medical imaging advanced visualization, clinical AI, and workflow automation, today announced updates to its Intuition platform with new best-in-class cardiac magnetic resonance (MR) medical imaging capabilities. These clinical innovations are now available across all deployment models and on the latest cloud infrastructure.

ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that James Salitan has joined the company as General Counsel.